Inflammatory Bowel Disease Monitor (Vol. 8, No. 1)

Faculty

This activity has 10 faculty members associated with it.
Click Here to View All

Rupert Abdalian, MD
Department of Medicine
Division of Gastroenterology
University of Toronto

Stephen Challacombe, FMedSci
Professor, Oral Medicine and Vice Dean
Director, External Development & Strategy
Department of Oral Medicine and Immunology
Dental Institute
Guy's, King's & St Thomas'
King's College London, UK

Pierre Desreumaux, PhD
Professor of Gastroenterology
Department of Hepatogastroenterology and Nutrition
Director of Research
Inflammatory Digestive Diseases
University of Lille, France

Michael Escudier, FDS, RCS
Lecturer, Human Disease
Honorary Consultant, Oral Medicine
Dental Institute
King's College London, UK

Miranda Lomer, PhD
Consultant Dietitian
Department of Gastroenterology
Guy’s and St Thomas’ NHS Trust
Nutritional Sciences Division
King’s College London, UK

Carlo Nunes, MD
Department of Gastroenterology
Guy’s & St Thomas’s NHS Foundation Trust , London, UK

Olivier Romano, MD
Department of Gastroenterology and Nutrition
Hospital Huriez
CHU Lille, France

Christel Rousseaux, PhD
Post doctoral research fellow
Department of Physiopathology of Intestinal Bowel Disease
Hospital Swynghedauw, Lille, France

Jeremy Sanderson, MD, FRCP
Department of Gastroenterology
Guy’s & St Thomas’s NHS Foundation Trust, London, UK

Mark S. Silverberg, MD, PhD
Assistant Professor, Department of Surgery and Medicine
Division of Gastroenterology
Mount Sinai Hospital
University of Toronto
Staff Physician, Division of Gastroenterology
Mount Sinai Hospital
University Health Network

Needs Statement

Inflammatory Bowel Disease Monitor, a CME-accredited educational program, systematically identifies, evaluates and places into clinical context the most important recent studies into the science and medicine of inflammatory bowel disease. It provides rapid access for busy specialists to a critical and clinically relevant review of the developments that will have most impact on their day-to-day practice and is designed to provide management options for clinicians to allow them to better diagnose and treat patients with IBD.

Each issue of Inflammatory Bowel Disease Monitor will present carefully constructed review articles, written by practicing specialists in gastroenterology and related disciplines and developed to equip readers with practical knowledge of the area under discussion. These articles are commissioned to support particular educational themes identified by the Editors-in-Chief, Editorial Advisory Board and readers. This issue of Inflammatory Bowel Disease Monitor presents three such leading articles.

Target Audience

This activity is designed to meet the educational needs of multidisciplinary clinicians and healthcare professionals involved in the care of patients with inflammatory bowel disease.

Objectives

1. Describe the three main parameters of the Vienna classification of Crohn’s disease;
2. Describe disease categorization according to the Montreal classification of Crohn’s disease and UC;
3. Describe novel markers of IBD, and their potential impact on current classification systems;
4. Describe downstream effects of 5-ASA-mediated inhibition of nuclear factor-B (NF-B);
5. Describe non-inflammatory, antineoplastic effects of 5-ASAs;
6. Describe antineoplastic effects of 5-ASAs in animal models of colorectal cancer, and in ex vivo studies in humans;
7. Describe the clinical features of OFG and similarities with Crohn’s disease characteristics;
8. Describe diagnostic features of OFG;
9. Describe dietary therapy and management of dietaryor topical-therapy refractory OFG.

Accreditation

Medicine
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the University of Kentucky College of Medicine and Remedica Medical Education. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this educational activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Each physician should claim only those hours of credit actually spent in the educational activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

Faculty Disclosure

Dr. Silverberg receives research support from Prometheus Laboratories.

Dr. Abdalian has no relevant financial interests to disclose.

Drs. Rousseaux and Romano have no relevant financial interests to disclose.

Dr. Desreumaux recevies consulting fees from, or serves on advisory boards for, Biofortis, Danisco France SAS, Danone France, Ferring, Giuliani S.p.A., Roquette, TxCell and UCB Pharma;  he also receives lecture fees from CME events indirectly supported by commercial sponsors (Ferring, Procter & Gamble, Schering Plough, Shire and UCB Pharma); and receives grant support from Astra Zeneca, Danisco France SAS, Danone France, Ferring, Giuliani S.p.A., Lesaffre, Ocera Therapeutics, Roquette, Sanofi- Synthelabo, UCB Pharma and Yoplait.

Drs. Nunes, Lomer, Escudier, Challacombe and Sanderson have no relevant financial interests to disclose.

Activity Sponsorship